<DOC>
	<DOCNO>NCT00449020</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , irinotecan , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give carboplatin irinotecan together radiation therapy follow docetaxel work treat patient newly diagnose stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Carboplatin , Irinotecan , Radiation Therapy Followed By Docetaxel Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate patient newly diagnose stage IIIA IIIB non-small cell lung cancer treat concurrent carboplatin , irinotecan hydrochloride , radiotherapy follow consolidation docetaxel . Secondary - Evaluate safety , toxicity , complication regimen patient . - Evaluate median survival , 1-year 2-year survival , time tumor progression patient . OUTLINE : - Chemoradiotherapy : Patients receive carboplatin IV 30 minute follow irinotecan hydrochloride IV 90 minute day 1 . Patients also undergo radiotherapy daily day 1-5 . Treatment repeat weekly 7 course absence disease progression unacceptable toxicity . - Consolidation chemotherapy : Beginning 3-4 week completion chemoradiotherapy , patient receive docetaxel IV 1 hour day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 4 year annually thereafter . PROJECTED ACCRUAL : A total 32 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIA IIIB disease Measurable disease , define ≥ 1 unidimensionally measurable lesion &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan No clinically significant malignant pleural pericardial effusion ( i.e. , stage IIIB wet disease ) PATIENT CHARACTERISTICS : ECOG performance status 01 Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin ≥ 8.0 g/dL Bilirubin normal Alkaline phosphatase ( AP ) , AST , ALT meet 1 follow criterion : AP normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) AP ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST ALT normal Creatinine &lt; 2.0 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment No New York Heart Association class IIIIV heart disease No history serious cardiac disease adequately control No document myocardial infarction within past 6 month No congestive heart failure No unstable angina No clinically significant arrhythmia No history severe hypersensitivity reaction drug formulate polysorbate 80 No peripheral neuropathy &gt; grade 1 No malignancy within past 5 year skin cancer PRIOR CONCURRENT THERAPY : More 3 week since prior major surgery No prior systemic chemotherapy , thoracic radiotherapy , surgical resection NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>